Genmab

Genmab GNMSF Stock

$509.60   1.163302%
Add to favorites
Market Cap
$31.42B
LOW - HIGH [24H]
$495.75 - $497.69
VOLUME [24H]
$6.00
P/E Ratio
43.55
Earnings per share
$11.70
ISIN
DK0010272202
Price   Prediction

Genmab Price Chart

Sorry, that's all we've gotfor now...

Genmab (GNMSF) stock price today is 509.6 USD on OTC Markets OTCPK (+1.16% on the day). Updated .

Genmab GNMSF Financial and Trading Overview

Genmab stock price 509.6 USD
Previous Close 541 USD
Open 497.25 USD
Bid 496.68 USD x 100
Ask 525.85 USD x 200
Day's Range 495.75 - 497.69 USD
52 Week Range 232.34 - 581 USD
Volume 6 USD
Avg. Volume 1.64K USD
Market Cap 30.62B USD
Beta (5Y Monthly) 0.518
PE Ratio (TTM) 42.441883
EPS (TTM) 11.7 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est N/A

GNMSF Valuation Measures

Enterprise Value 35.21B USD
Trailing P/E 42.441883
Forward P/E 35.93126
PEG Ratio (5 yr expected) 4.55
Price/Sales (ttm) 7.127139
Price/Book (mrq) 4.9629703
Enterprise Value/Revenue 8.196
Enterprise Value/EBITDA 25.967

Trading Information

Genmab Stock Price History

Beta (5Y Monthly) 0.518
52-Week Change 64.62%
S&P500 52-Week Change 8.67%
52 Week High 581 USD
52 Week Low 232.34 USD
50-Day Moving Average 425.51 USD
200-Day Moving Average 318.13 USD

GNMSF Share Statistics

Avg. Volume (3 month) 1.64K USD
Avg. Daily Volume (10-Days) 520 USD
Shares Outstanding 61.66M
Float 58.96M
Short Ratio N/A
% Held by Insiders 1.11%
% Held by Institutions 46.37%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 16.96%
Operating Margin (ttm) 30.63%
Gross Margin 92.66%
EBITDA Margin 31.56%

Management Effectiveness

Return on Assets (ttm) 8.24%
Return on Equity (ttm) 12.06%

Income Statement

Revenue (ttm) 4.3B USD
Revenue Per Share (ttm) 69.88 USD
Quarterly Revenue Growth (yoy) 16.10%
Gross Profit (ttm) 3.98B USD
EBITDA 1.36B USD
Net Income Avi to Common (ttm) 729M USD
Diluted EPS (ttm) 11.7
Quarterly Earnings Growth (yoy) -14.69%

Balance Sheet

Total Cash (mrq) 1.87B USD
Total Cash Per Share (mrq) 29.56 USD
Total Debt (mrq) 5.2B USD
Total Debt/Equity (mrq) 82.08 USD
Current Ratio (mrq) 2.454
Book Value Per Share (mrq) 100.055

Cash Flow Statement

Operating Cash Flow (ttm) 875M USD
Levered Free Cash Flow (ttm) 854.88M USD

Profile of Genmab

Country United States
State N/A
City Copenhagen
Address Carl Jacobsens Vej 30
ZIP 2500
Phone 45 70 20 27 28
Website https://www.genmab.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 3244

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Q&A For Genmab Stock

What is a current GNMSF stock price?

Genmab GNMSF stock price today per share is 509.6 USD.

How to purchase Genmab stock?

You can buy GNMSF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Genmab?

The stock symbol or ticker of Genmab is GNMSF.

Which industry does the Genmab company belong to?

The Genmab industry is Biotechnology.

How many shares does Genmab have in circulation?

The max supply of Genmab shares is 61.66M.

What is Genmab Price to Earnings Ratio (PE Ratio)?

Genmab PE Ratio is 43.55555700 now.

What was Genmab earnings per share over the trailing 12 months (TTM)?

Genmab EPS is 11.7 USD over the trailing 12 months.

Which sector does the Genmab company belong to?

The Genmab sector is Healthcare.

$2.08T
Total marketcap
$155.84B
Total volume
BTC 57.96%   •   ETH 9.91%
Dominance
Select currency